CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 29, 2013--
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it has
entered into a Materials Cooperative Research and Development Agreement
(M-CRADA) with the National Cancer Institute (NCI) to evaluate the
Company’s Toll-like receptor (TLR) antagonists as a potential approach
to the treatment of certain genetically defined B-cell lymphomas.
"We are pleased to have entered into this agreement, and we look forward
to communicating further on it as the work underway proceeds," said
Sudhir Agrawal, D. Phil., Chief Executive Officer of Idera
Pharmaceuticals.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals technology platform involves creating novel
synthetic RNA- and DNA-based compounds to modulate immune responses.
Idera has applied this platform to develop proprietary Toll-like
receptor (TLR) antagonists as immunomodulatory drug candidates.
Toll-like receptor antagonists block the overactivation of immune
factors which can cause a range of pathological effects. Idera is
conducting clinical development of TLR antagonists in autoimmune and
inflammatory diseases, and preclinical development of their use in
certain genetically defined lymphomas. More information on Idera is
available at iderapharma.com.
Forward Looking Statements
This press release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and uncertainties.
For this purpose, any statements contained herein that are not
statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, the words "believes,"
"anticipates," "plans," "expects," "estimates," "intends," "should,"
"could," "will," "may," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors that
could cause Idera's actual results to differ materially from those
indicated by such forward-looking statements, including whether Idera’s
cash resources will be sufficient to fund the Company’s continuing
operations and the further development of the Company’s programs;
whether results obtained in early research and preclinical studies will
be indicative of the results that will be generated in future
preclinical and clinical studies; whether products based on Idera's
technology will advance into or through the clinical trial process on a
timely basis or at all and receive approval from the United States Food
and Drug Administration or equivalent foreign regulatory agencies;
whether, if the Company's products receive approval, they will be
successfully distributed and marketed; and such other important factors
as are set forth under the caption "Risk Factors" in Idera's Quarterly
Report on Form 10-Q for the quarter ended June 30, 2013, which important
factors are incorporated herein by reference. Idera disclaims any
intention or obligation to update any forward-looking statements.
Source: Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com
